STOCK TITAN

Cerus - CERS STOCK NEWS

Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.

Cerus Corporation (CERS) is a pioneering biomedical products company dedicated to enhancing blood safety worldwide. The company’s flagship technology, the INTERCEPT Blood System, aims to mitigate the risk of transfusion-transmitted diseases by inactivating a broad spectrum of pathogens, including viruses, bacteria, and parasites present in donated blood. Utilizing a unique nucleic acid targeting mechanism, the INTERCEPT system offers protection against established threats like Hepatitis B and C, HIV, West Nile Virus, and bacteria, while also being designed to inactivate emerging pathogens such as Influenza, Malaria, and Dengue.

Cerus Corporation markets and sells the INTERCEPT Blood System for both platelets and plasma in various regions including Europe, Russia, the Middle East, and selected countries globally. The INTERCEPT Red Blood Cell system is currently in clinical development, highlighting the company’s ongoing efforts to broaden its product offerings and enhance blood safety further.

Recent achievements for Cerus include expanding market reach, securing regulatory approvals, and forging key partnerships to strengthen its global presence. Financially, Cerus remains focused on sustaining growth through innovation and strategic collaborations.

By prioritizing safety and efficacy, Cerus Corporation plays a critical role in the field of blood transfusion safety, making significant strides in protecting public health on a global scale.

Rhea-AI Summary

Cerus (CERS) reported strong financial results for full-year and Q4 2024. Full-year product revenue reached $180.3 million, up 15% year-over-year, while Q4 product revenue was $50.8 million, a 9% increase. The company achieved significant financial improvements, including a 40% reduction in GAAP net loss to $20.9 million and positive non-GAAP adjusted EBITDA of $5.7 million for 2024.

Notable achievements include four consecutive quarters of positive operating cash flows, totaling $11.4 million for the year, a $55 million improvement from 2023. The INTERCEPT Fibrinogen Complex (IFC) product showed strong growth, with full-year revenue of $9.2 million, up 42% from the previous year.

The company reiterated its 2025 product revenue guidance of $194-200 million, including $12-15 million for IFC, projecting 8-11% growth from 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Cerus (Nasdaq: CERS) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management team is scheduled to present at a fireside chat on Wednesday, March 5, at 11:10 a.m. EST. The presentation will be accessible through a live webcast, with a replay available for 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Cerus (Nasdaq: CERS) has scheduled the release of its fourth quarter and full-year 2024 financial results for Thursday, February 20, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day, featuring management discussions on financial results, business overview, and outlook.

Interested participants can access the webcast and presentation slides through Cerus' Investor Relations webpage at http://ir.cerus.com. While early joining is encouraged (10 minutes prior), it's not mandatory. A replay of the event will be available on the company's website approximately three hours after the call until March 6, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Cerus (CERS) reported preliminary full-year 2024 product revenue of $180.3 million, exceeding their guidance of $177-$179 million and marking a 15% increase over 2023. The growth was driven by strong performance in their INTERCEPT platelet franchise and IFC business, which grew 42% to reach $9.2 million in revenue.

For 2025, Cerus projects product revenue between $194-$200 million, representing 8-11% year-over-year growth. IFC revenue is expected to range from $12-$15 million. The company anticipates Q1 2025 product revenue growth of 10-15% compared to Q1 2024. Future initiatives include the planned LED Illuminator launch in Europe and geographic expansion efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
none
-
Rhea-AI Summary

Cerus (Nasdaq: CERS) has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2024 Healthcare Conference on Monday, November 18th at 4:10 PM ET, and attend the Craig-Hallum Alpha Select Conference on Tuesday, November 19th. A live webcast of the Stifel conference presentation will be available online, with a replay accessible on the company's website following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
conferences
-
Rhea-AI Summary

Cerus (CERS) reported strong Q3 2024 financial results with product revenue increasing 16% to $46.0 million. The company raised its full-year 2024 product revenue guidance to $177-179 million. Q3 highlights include a new $248 million BARDA contract for INTERCEPT RBCs, expanded U.S. manufacturing capacity for INTERCEPT Fibrinogen Complex, and improved financial metrics with GAAP net loss narrowing to $2.9 million. Product gross margin improved to 56.9%, and the company generated positive operating cash flows of $4.1 million. However, CE Mark review for INTERCEPT RBCs concluded without approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.72%
Tags
Rhea-AI Summary

Cerus (Nasdaq: CERS) has announced that it will release its third quarter 2024 financial results on Wednesday, October 30, 2024, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss the financial results and provide a general business overview and outlook.

Interested parties can listen to the live webcast and view presentation slides on the Investor Relations page of Cerus' website at http://ir.cerus.com. Participants are encouraged to register for the call and join 10 minutes before the event starts. A replay of the call will be available on Cerus' website approximately three hours after the call and will remain accessible until November 20, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
-
Rhea-AI Summary

Cerus (CERS) announced a selection of abstracts to be presented at the 2024 AABB Annual Meeting in Houston, Texas from October 19-22. The presentations highlight real-world utilization of INTERCEPT-treated blood products, including INTERCEPT Fibrinogen Complex, and recent findings from the Phase 3 ReCePI Clinical Trial.

Key presentations include:

  • Outcomes of the ReCePI Phase III Clinical Trial evaluating pathogen-reduced red cells in cardiac surgery
  • Efficiency of INTERCEPT Fibrinogen Complex vs traditional cryoprecipitate
  • Phase IV TOPCLOT trial comparing pathogen-reduced cryoprecipitate to cryoprecipitated AHF in cardiac surgery
  • HLA alloimmunization and treatment-emergent antibodies in the ReCePI study

Poster presentations will cover topics such as pathogen reduction efficacy, next-generation illuminator development, and implementation of pathogen-reduced blood products. Cerus will also host an industry workshop on current experiences and future developments with the INTERCEPT Blood System.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
-
Rhea-AI Summary

Cerus (Nasdaq:CERS) has provided updates on its INTERCEPT red blood cell (RBC) programs in the U.S. and Europe. In the U.S., Cerus has secured a new $248 million contract with BARDA to support the program through FDA approval and commercialization. The company recently announced positive topline results for the ReCePI study, a pivotal U.S. Phase 3 clinical trial.

In Europe, the CE Mark review under the Medical Device Regulation (MDR) has concluded without approval. Cerus is assessing strategies for a potential new regulatory submission. The company remains confident in the need for pathogen inactivated RBCs and plans to leverage additional data, including results from the U.S. Phase 3 ReCePI trial, for a potential new CE Mark submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.44%
Tags
none
Rhea-AI Summary

Cerus (Nasdaq: CERS) announced strong Q2 2024 financial results and increased its full-year 2024 product revenue guidance. Key highlights include:

- Q2 2024 product revenue: $45.1 million, up 16% year-over-year
- H1 2024 product revenue: $83.4 million, up 20% year-over-year
- Full-year 2024 product revenue guidance raised to $175-178 million
- Q2 2024 GAAP net loss narrowed to $5.8 million
- Q2 2024 non-GAAP adjusted EBITDA: $0.8 million
- Positive operating cash flows of $2.4 million year-to-date
- Cash and investments: $71.2 million as of June 30, 2024

The company reported strong growth in its platelets business, particularly in North America, and accelerating adoption of INTERCEPT Fibrinogen Complex (IFC). Cerus remains committed to achieving adjusted EBITDA breakeven for the full-year 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.2%
Tags

FAQ

What is the current stock price of Cerus (CERS)?

The current stock price of Cerus (CERS) is $1.65 as of February 21, 2025.

What is the market cap of Cerus (CERS)?

The market cap of Cerus (CERS) is approximately 323.1M.

What is Cerus Corporation's main focus?

Cerus Corporation focuses on commercializing the INTERCEPT Blood System to enhance blood safety by inactivating pathogens in donated blood.

What pathogens does the INTERCEPT Blood System target?

The INTERCEPT Blood System targets a wide range of pathogens including viruses (like HIV and Hepatitis), bacteria, and parasites.

Where is the INTERCEPT Blood System marketed?

The INTERCEPT Blood System is marketed in Europe, Russia, the Middle East, and selected countries worldwide.

What products does Cerus Corporation offer?

Cerus offers the INTERCEPT Blood System for both platelets and plasma, with a red blood cell system in clinical development.

What are some recent achievements of Cerus Corporation?

Recent achievements include expanding market reach, securing regulatory approvals, and establishing key partnerships.

How does the INTERCEPT Blood System work?

The system uses a nucleic acid targeting mechanism to inactivate pathogens in donated blood, reducing the risk of transfusion-transmitted diseases.

What financial strategies does Cerus Corporation employ?

Cerus focuses on sustaining growth through innovation and strategic collaborations.

Is Cerus Corporation involved in research for emerging pathogens?

Yes, the INTERCEPT system is designed to inactivate emerging pathogens such as Influenza, Malaria, and Dengue.

What regions are key markets for Cerus Corporation?

Key markets include Europe, Russia, the Middle East, and selected countries in other regions.

What segment does Cerus Corporation operate in?

Cerus operates in the blood safety segment, focusing on enhancing transfusion safety.
Cerus

Nasdaq:CERS

CERS Rankings

CERS Stock Data

323.14M
176.84M
3.38%
78.03%
4.69%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
CONCORD